Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Inovio Pharmaceuticals and its officers/directors, following a significant stock price drop after FDA news regarding its drug application [1][4]. Group 1: FDA Announcement and Stock Impact - On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107, a treatment for recurrent respiratory papillomatosis, but did not find sufficient information for accelerated approval [3]. - Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share on the same day [4]. Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Inovio regarding claims of potential securities fraud and is encouraging them to contact the firm for further information [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Cogent Communications Holdings, Inc. and its officers or directors [1] Financial Performance - On November 6, 2025, Cogent reported a year-over-year service revenue decline of nearly 6% for the third quarter of 2025 [3] - The company announced a drastic dividend cut of 98%, reducing it from $1.015 per share to $0.02 per share [3] - Following the announcement, Cogent's stock price dropped by $13.35 per share, or 34.86%, closing at $24.95 per share on the same day [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Apogee Enterprises, Inc. and its officers or directors [1] Financial Performance - On January 7, 2025, Apogee reported third-quarter financial results for the 2026 fiscal year, with sales of $355.3 million, which fell short of the consensus estimate of $348.6 million [3] - The CEO attributed the disappointing results to "higher aluminum, restructuring and health insurance costs" [3] - Following the announcement, Apogee's stock price decreased by $5.18 per share, or 13.89%, closing at $32.11 per share on January 7, 2026 [3]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving BigBear.ai Holdings, Inc. and its officers or directors [1] Group 1: Company Performance - Cantor analysts downgraded BigBear from Overweight to Neutral on January 7, 2026, citing a 20% year-over-year revenue decline [3] - The company reported an adjusted EBITDA of ($9.4 million) in Q3 2025 and an operating margin of (66.0%) [3] - Following the downgrade, BigBear's stock price decreased by $0.42 per share, or 6.55%, closing at $5.99 per share on January 7, 2026 [3] Group 2: Legal Investigation - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud [1]

Core Viewpoint - Sigma Lithium Corporation is under investigation for potential securities fraud and unlawful business practices, following a downgrade by Bank of America due to unresolved operational and liquidity issues [1][3]. Group 1: Investigation and Legal Actions - Pomerantz LLP is investigating claims on behalf of Sigma Lithium investors regarding possible securities fraud or other unlawful business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information about the class action [2]. Group 2: Stock Performance and Analyst Downgrade - On January 8, 2026, Bank of America downgraded Sigma Lithium from Neutral to Underperform, citing unresolved operational and liquidity issues [3]. - Following the downgrade, Sigma Lithium's stock price decreased by $2.36 per share, or 15.07%, closing at $13.30 per share on the same day [3].

Core Viewpoint - Vanda Pharmaceuticals Inc. is under investigation for potential securities fraud and unlawful business practices following the FDA's rejection of its supplemental New Drug Application for HETLIOZ® [1][3]. Group 1: FDA Decision - On January 8, 2026, Vanda announced that the FDA concluded the supplemental New Drug Application for HETLIOZ® for jet lag disorder cannot be approved in its current form [3]. - The FDA acknowledged positive efficacy from Vanda's clinical trials but determined that the data did not provide substantial evidence of effectiveness for jet lag disorder due to the inadequacy of the controlled phase advance protocols [3]. - Following the FDA's announcement, Vanda's stock price fell by $1.20 per share, or 14.05%, closing at $7.34 per share on January 8, 2026 [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Vanda's investors regarding potential securities fraud or other unlawful business practices by the company and its officers and/or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2][6]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [4]. - The firm has a legacy of recovering multimillion-dollar damages awards for class members over its 85-year history [4].

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. regarding allegations of securities fraud and unlawful business practices following a significant drop in share price after its IPO [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Fermi and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until March 6, 2026, to request to be appointed as Lead Plaintiff if they purchased Fermi securities related to its IPO [2]. Group 2: IPO and Subsequent Developments - Fermi completed its IPO on October 1, 2025, offering 32.5 million shares at a price of $21.00 per share [4]. - On December 12, 2025, Fermi announced the termination of a $150 million Advance in Aid of Construction Agreement for its Project Matador data center, which negatively impacted investor confidence and share price [4].

Core Viewpoint - A class action lawsuit has been filed against Bitdeer Technologies Group for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves allegations against Bitdeer and certain officers and/or directors regarding securities fraud [2]. - Investors who purchased Bitdeer securities during the Class Period have until February 2, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Financial Performance - On November 10, 2025, Bitdeer reported unaudited financial results for Q3 2025, showing earnings per share of -$1.28, which was significantly below the consensus estimate of -$0.22 [4]. - Following the earnings report, Bitdeer's stock price dropped by $2.63, or 14.9%, closing at $15.02 per share on November 11, 2025 [4]. - The company also disclosed significant delays in the development of its next-generation Seal 04 ASIC chip [4].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves allegations against Alexandria and certain officers and/or directors regarding securities fraud [2]. - Investors have until January 26, 2026, to request to be appointed as Lead Plaintiff if they purchased Alexandria securities during the Class Period [2]. Group 2: Financial Performance - On October 27, 2025, Alexandria reported disappointing financial results for Q3 2025, including a reduction in full-year 2025 funds from operations (FFO) guidance [4]. - The company cited lower occupancy rates, slower leasing activity, and a significant real estate impairment charge of $323.9 million, with $206 million related to its Long Island City property [4]. Group 3: Market Reaction - Following the announcement of the financial results, Alexandria's stock price dropped by $14.93 per share, or 19.17%, closing at $62.94 per share on October 28, 2025 [5].

Core Viewpoint - A class action lawsuit has been filed against Gauzy Ltd. regarding allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The class action lawsuit involves Gauzy and certain officers and/or directors accused of engaging in securities fraud or other unlawful business practices [2]. - Investors have until February 6, 2026, to request to be appointed as Lead Plaintiff if they purchased or acquired Gauzy securities during the Class Period [2]. Group 2: Financial Performance and Impact - On November 14, 2025, Gauzy announced a delay in releasing its financial results for Q3 2025 due to insolvency proceedings ordered by the Commercial Court of Lyon, France, affecting three subsidiaries [4]. - Following the announcement of the insolvency proceedings, Gauzy's stock price dropped by $1.35 per share, or 33.58%, closing at $2.67 per share on the same day [4].